Valneva SE (VALN) Net Income towards Common Stockholders (2021 - 2026)
Valneva SE (VALN) reported Net Income towards Common Stockholders of -$27.7 million for Q1 2026, down 342.51% on a YoY basis from $11.4 million in Q1 2025, and up 52.41% sequentially from -$58.3 million in Q4 2025.
Valneva SE (VALN) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$27.7 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 342.51% year-over-year to -$27.7 million; the trailing twelve-month figure through Mar 2026 stood at -$141.7 million (down 116.52% YoY), and the FY2025 full-year result was -$134.1 million, down 1029.61% from the prior year.
- Net Income towards Common Stockholders grew to -$27.7 million in Q1 2026, from -$58.3 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $74.1 million in Q1 2024 to a low of -$2.1 billion in Q3 2022.
- A 5-year average of -$151.1 million and a median of -$24.2 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders tumbled 1033.07% in 2022 and soared 516.53% in 2024, its largest moves.
- Tracing VALN's Net Income towards Common Stockholders over 5 years: stood at -$57.5 million in 2022, then jumped by 53.39% to -$26.8 million in 2023, then gained by 16.72% to -$22.3 million in 2024, then tumbled by 161.21% to -$58.3 million in 2025, then soared by 52.41% to -$27.7 million in 2026.
- Business Quant data shows VALN's Net Income towards Common Stockholders at -$27.7 million in Q1 2026, -$58.3 million in Q4 2025, and -$43.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Valneva SE | 811.46 Mn | 688.23 Mn | 5.08 Mn | -27.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.74 Mn |
| Dec 31, 2025 | -58.29 Mn |
| Sep 30, 2025 | -43.39 Mn |
| Jun 30, 2025 | -12.30 Mn |
| Mar 31, 2025 | -6.27 Mn |
| Dec 31, 2024 | -22.32 Mn |
| Sep 30, 2024 | -13.67 Mn |
| Jun 30, 2024 | -23.20 Mn |
| Mar 31, 2024 | 74.10 Mn |
| Dec 31, 2023 | -26.80 Mn |
| Sep 30, 2023 | -24.18 Mn |
| Jun 30, 2023 | -20.03 Mn |
| Mar 31, 2023 | -17.79 Mn |
| Dec 31, 2022 | -57.49 Mn |
| Sep 30, 2022 | -2.11 Bn |
| Jun 30, 2022 | -156.31 Mn |
| Mar 31, 2022 | -28.10 Mn |
| Dec 31, 2021 | 193.58 Mn |
| Sep 30, 2021 | -185.83 Mn |
| Jun 30, 2021 | -68.19 Mn |